Gesundheitsökonomie & Qualitätsmanagement , Thieme Verlag Heft 5-2009, Jahrgang 14) ISSN 1432-2625 Seite(n) 245 bis 252 DOI: 10.1055/s-0028-1109707 CareLit-Dokument-Nr: 318600 |
|
Zusammenfassung Omega-3-Fettsäuren (FS) Eicosapentaensäure (EPA) und Docosahexaensäure (DHA) sind wichtige Bestandteile der Nahrung. Gegenwärtig ist jedoch die Aufnahme dieser essenziellen mehrfach ungesättigten Fettsäuren im Rahmen der täglichen Ernährung unzureichend. Es soll daher darauf geachtet werden, dass EPA und DHA dem Organismus in ausreichender Menge, vor allem in Form von Fisch und Fischprodukten, zugeführt werden. Wird eine optimale Versorgung des Körpers durch die normale Nahrungszufuhr nicht sichergestellt, können Supplementationsmöglichkeiten überlegt werden. In der vorliegenden Arbeit wird der Stellenwert von Omega-3-FS für Prävention und Therapie unterschiedlicher Erkrankungen sowie ihre Wirkmechanismen diskutiert. Es wird weiter auf die praktischen Verfahren eingegangen, den individuellen Omega-3-Status zu bestimmen und durch unterschiedliche Maßnahmen eine ausreichende Zufuhr von Omega-3-FS zu gewährleisten. Abstract Omega-3 fatty acids (FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are important components of nutrition. Unfortunately, the intake of these essential polyunsaturated fatty acids is often insufficient in western countries. Therefore, it is of particular importance, that the organism receives adequate amounts of EPA and DHA from nourishment (fish and fish products). If the optimal intake of Omega-3 FA from nutrition can not be achieved in an individual, supplementation should be considered. In the present review, the role of Omega-3 fatty acids in prevention and therapy of various diseases, as well as their mechanisms of action, are discussed. Furthermore, the paper addresses practical options to determine the individual Omega-3 status and describes different possibilities to assure sufficient intake of Omega-3 FA. Schlüsselwörter Omega-3-Fettsäuren - Prävention - Therapie - Eicosapentaensäure - Docosahexaensäure Key words Omega-3 fatty acids - prevention - therapy - eicosapentaenoic acid - docosahexaenoic acid Literatur 1 Bang H O, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976; 200 69-73 Google Scholar 2 Khanapure S P, Garvey D S, Janero D R. et al . Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007; 7 311-340 Google Scholar 3 Simopoulos A P. The importance of the ratio of omega-6 /omega-3 essential fatty acids. Biomed Pharmacother. 2002; 56 365-379 Google Scholar 4 Brenna J T, Salem Jr N, Sinclair A J. et al . alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009; 80 85-91 Google Scholar 5 Plourde M, Cunnane S C. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab. 2007; 32 619-634 Google Scholar 6 Appleton K M, Rogers P J, Ness A R. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev. 2008; 21 13-41 Google Scholar 7 Brouwer I A. Omega-3 PUFA: good or bad for prostate cancer?. Prostaglandins Leukot Essent Fatty Acids. 2008; 79 97-99 Google Scholar 8 Carpentier Y A, Portois L, Malaisse W J. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr. 2006; 83 1499S-1504S Google Scholar 9 Cole G M, Ma Q L, Frautschy S A. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009; Jun 10. Epub ahead of print Google Scholar 10 Mayser P, Grimm H, Grimminger F. n-3 fatty acids in psoriasis. Br J Nutr. 2002; 87 (Suppl 1) S77-S82 Google Scholar 11 Turner D, Zlotkin S H, Shah P S. et al . Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009; (1) CD006320 Google Scholar 12 McKarney C, Everard M, N’Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev. 2007; (4) CD002201 Google Scholar 13 Mehta L R, Dworkin R H, Schwid S R. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol. 2009; 5 82-92 Google Scholar 14 Kris-Etherton P M, Grieger J A, Etherton T D. Dietary reference intakes for DHA and EPA. Prostaglandins Leukot Essent Fatty Acids. 2009; Jun 12. Epub ahead of print Google Scholar 15 Hoy S M, Keating G M. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs. 2009; 69 1077-1105 Google Scholar 16 Cetin I, Koletzko B. Long-chain omega-3 fatty acid supply in pregnancy and lactation. Curr Opin Clin Nutr Metab Care. 2008; 11 297-302 Google Scholar 17 Cicero A F, Ertek S, Borghi C. Omega-3 polyunsaturated Fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 2009; 7 330-337 Google Scholar 18 Goldberg R J, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007; 129 210-223 Google Scholar 19 Proudman S M, Cleland L G, James M J. Dietary omega-3 fats for treatment of inflammatory joint disease: efficacy and utility. Rheum Dis Clin North Am. 2008; 34 469-479 Google Scholar 20 Omacor (Omega-3-Säurenethylester 90 1000 mg). Fachinformation. Stand November 2007 Google Scholar 21 Albert C M, Campos H, Stampfer M J. et al . Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002; 346 1113-1118 Google Scholar 22 Burr M L, Fehily A M, Gilbert J F. et al . Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989; 2 757-761 Google Scholar 23 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354 447-455 Google Scholar 24 Senges J, Schiele R, Schneider S. et al .Randomized trial of omega-3 fatty acids on top of modern therapy after acute myocardial infarction: the OMEGA trial (oral presentation). 58th Annual Scientific Session of the American College of Cardiology 2009 Mar 29 – 31 Google Scholar 25 Rauch B, Schiele R, Schneider S. et al . Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. Cardiovasc Drugs Ther. 2006; 20 365-375 Google Scholar 26 Tavazzi L, Tognoni G, Franzosi M G. et al . Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004; 6 635-641 Google Scholar 27 Tavazzi L, Maggioni A P, Marchioli R. et al . Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 1223-1230 Google Scholar 28 Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009; 23 41-48 Google Scholar 29 Simopoulos A P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21 495-505 Google Scholar 30 Arterburn L M, Hall E B, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006; 83 1467S-1476S Google Scholar 31 London B, Albert C, Anderson M E. et al . Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007; 116 e320-e335 Google Scholar 32 Schacky von C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both?. Curr Opin Clin Nutr Metab Care. 2008; 11 94-99 Google Scholar 33 Christensen J H, Schmidt E B. Autonomic nervous system, heart rate variability and n-3 fatty acids. J Cardiovasc Med. 2007; 8 (Suppl 1) S19-S22 Google Scholar 34 Calo L, Bianconi L, Colivicchi F. et al . N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005; 45 1723-1728 Google Scholar 35 Pratt C M, Reiffel J A, Ellenbogen K A. et al . Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009; 158 163-169 e161-e163 Google Scholar 36 Macchia A, Varini S, Grancelli H. et al . The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J. 2009; 157 423-427 Google Scholar 37 Thies F, Garry J M, Yaqoob P. et al . Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003; 361 477-485 Google Scholar 38 Balk E M, Lichtenstein A H, Chung M. et al . Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis. 2006; 184 237-246 Google Scholar 39 Schacky von C, Fischer S, Weber P C. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985; 76 1626-1631 Google Scholar 40 Mindrescu C, Gupta R P, Hermance E V. et al . Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vasc Health Risk Manag. 2008; 4 1439-1447 Google Scholar 41 Wright S A, O’Prey F M, McHenry M T. et al . A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008; 67 841-848 Google Scholar 42 Goodfellow J, Bellamy M F, Ramsey M W. et al . Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000; 35 265-270 Google Scholar 43 Ross B M, Seguin J, Sieswerda L E. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids Health Dis. 2007; 6 21 Google Scholar 44 Lin P Y, Su K P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007; 68 1056-1061 Google Scholar 45 Montgomery P, Richardson A J. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev. 2008; (2) CD005169 Google Scholar 46 Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol. 2009; 51 580-592 Google Scholar 47 Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005; 65 1051-1059 Google Scholar 48 Romano C, Cucchiara S, Barabino A. et al . Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005; 11 7118-7121 Google Scholar 49 Stenson W F, Cort D, Rodgers J. et al . Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992; 116 609-614 Google Scholar 50 Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992; 87 432-437 Google Scholar 51 Berbert A A, Kondo C R, Almendra C L. et al . Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition. 2005; 21 131-136 Google Scholar 52 Mayser P, Mrowietz U, Arenberger P. et al . Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998; 38 539-547 Google Scholar 53 Dunstan J A, Mori T A, Barden A. et al . Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol. 2003; 112 1178-1184 Google Scholar 54 Mayser P, Mayer K, Mahloudjian M. et al . A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. JPEN J Parenter Enteral Nutr. 2002; 26 151-158 Google Scholar 55 Turner D, Steinhart A H, Griffiths A M. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007; (3) CD006443 Google Scholar 56 Soyland E, Funk J, Rajka G. et al . Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med. 1993; 328 1812-1816 Google Scholar 57 Anandan C, Nurmatov U, Sheikh A. Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta-analysis. Allergy. 2009; 64 840-848 Google Scholar 58 Auestad N, Scott D T, Janowsky J S. et al . Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics. 2003; 112 e177-e183 Google Scholar 59 Fleith M, Clandinin M T. Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Nutr. 2005; 45 205-229 Google Scholar 60 Koletzko B, Lien E, Agostoni C. et al . The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med. 2008; 36 5-14 Google Scholar 61 Helland I B, Smith L, Saarem K. et al . Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics. 2003; 111 e39-e44 Google Scholar 62 Lichtenstein A H, Appel L J, Brands M. et al . Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006; 114 82-96 Google Scholar 63 Kris-Etherton P M, Harris W S, Appel L J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106 2747-2757 Google Scholar 64 De Backer G, Ambrosioni E, Borch-Johnsen K. et al . European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24 1601-1610 Google Scholar 65 Harris W S. International recommendations for consumption of long-chain omega-3 fatty acids. J Cardiovasc Med. 2007; 8 (Suppl 1) S50-S52 Google Scholar 66 FDA .Substances Affirmed as Generally Recognized as Safe: Menhaden Oil. Federal Register: Volume 69, Number 10. January 15, 2004 http://www.epa.gov/EPA-IMPACT/ 2004 /January/Day-15 /i811.htm Google Scholar 67 Dyerberg J, Bang H O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979; 2 433-435 Google Scholar 68 Bays H E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007; 99 35C-43C Google Scholar 69 Siscovick D S, Raghunathan T E, King I. et al . Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Jama. 1995; 274 1363-1367 Google Scholar 70 Harris W S, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev Med. 2004; 39 212-220 Google Scholar 71 Harris W S. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr. 2008; 87 1997S-2002S Google Scholar 72 Harris W S. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res. 2007; 55 217-223 Google Scholar 73 Schacky von C. Cardiovascular disease prevention and treatment. Prostaglandins Leukot Essent Fatty Acids. 2009; Jun 9. Epub ahead of print Google Scholar 74 Iso H, Kobayashi M, Ishihara J. et al . Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation. 2006; 113 195-202 Google Scholar 75 Block R C, Harris W S, Reid K J. et al . EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 2008; 197 821-828 Google Scholar 76 Max Rubner-Institut. Bundesforschungsinstitut für Ernährung und Lebensmittel .Nationale Verzehrsstudie II. Ergebnisbericht, Teil 2. 2008 Google Scholar 77 Weaver K L, Ivester P, Chilton J A. et al . The content of favorable and unfavorable polyunsaturated fatty acids found in commonly eaten fish. J Am Diet Assoc. 2008; 108 1178-1185 Google Scholar 78 USDA National Nutrient Database for Standard Reference (SR 20). US Dept of Agriculture, Agricultural Research Service Web site http://nal.usda.gov/fnic/foodcomp Google Scholar 79 Domingo J L, Bocio A, Falco G. et al . Benefits and risks of fish consumption Part I. A quantitative analysis of the intake of omega-3 fatty acids and chemical contaminants. Toxicology. 2007; 230 219-226 Google Scholar 80 Methyl mercury in fish and fishery products. Information note. European Commission: Health & Consumer Protection Directorate-General. Directorate D – Food Safety: production and distribution chain. Brussels; 12 May 2004 Google Scholar 81 Harris W S. n-3 Fatty acid fortification: opportunities and obstacles. Br J Nutr. 2007; 97 593-595 Google Scholar 82 Kirch W, Badura B. Prävention. Heidelberg; Springer 2005 Google Scholar 83 Kirch W, Badura B, Pfaff H. Prävention und Versorgungsforschung. Heidelberg; Springer 2007 Google Scholar Evgeny Idelevich Institut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität Dresden Fiedlerstraße 27 01307 Dresden Email: evgeny.idelevich@tu-dresden.de
{{detailinfo.data.api.data.document[0].apa}}
{{detailinfo.data.api.data.document[0].vancouver}}
{{detailinfo.data.api.data.document[0].harvard}}